vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and WIDEPOINT CORP (WYY). Click either name above to swap in a different company.

WIDEPOINT CORP is the larger business by last-quarter revenue ($42.3M vs $38.3M, roughly 1.1× ImmunityBio, Inc.). WIDEPOINT CORP runs the higher net margin — -2.0% vs -161.8%, a 159.8% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 12.3%). WIDEPOINT CORP produced more free cash flow last quarter ($-270.0K vs $-71.3M).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

WidePoint Corporation is an American company based in Fairfax, Virginia that provides technology-based products and services to the government sector and commercial markets in the United States. The company holds a patent for a digital parsing tool that allows users to access accounts through a secure repository gateway, established using asymmetric authentication employed as public key infrastructure (PKI). WidePoint provides smart card identity verification, wireless expense management, pen...

IBRX vs WYY — Head-to-Head

Bigger by revenue
WYY
WYY
1.1× larger
WYY
$42.3M
$38.3M
IBRX
Growing faster (revenue YoY)
IBRX
IBRX
+394.7% gap
IBRX
407.0%
12.3%
WYY
Higher net margin
WYY
WYY
159.8% more per $
WYY
-2.0%
-161.8%
IBRX
More free cash flow
WYY
WYY
$71.0M more FCF
WYY
$-270.0K
$-71.3M
IBRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IBRX
IBRX
WYY
WYY
Revenue
$38.3M
$42.3M
Net Profit
$-61.9M
$-849.4K
Gross Margin
99.0%
13.8%
Operating Margin
-169.0%
-1.9%
Net Margin
-161.8%
-2.0%
Revenue YoY
407.0%
12.3%
Net Profit YoY
-4.7%
-138.3%
EPS (diluted)
$-0.06
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
WYY
WYY
Q4 25
$38.3M
$42.3M
Q3 25
$32.1M
$36.1M
Q2 25
$26.4M
$37.9M
Q1 25
$16.5M
$34.2M
Q4 24
$7.6M
$37.7M
Q3 24
$6.1M
$34.6M
Q2 24
$36.0M
Q1 24
$34.2M
Net Profit
IBRX
IBRX
WYY
WYY
Q4 25
$-61.9M
$-849.4K
Q3 25
$-67.3M
$-559.2K
Q2 25
$-92.6M
$-618.5K
Q1 25
$-129.6M
$-724.1K
Q4 24
$-59.2M
$-356.4K
Q3 24
$-85.7M
$-425.2K
Q2 24
$-499.6K
Q1 24
$-653.1K
Gross Margin
IBRX
IBRX
WYY
WYY
Q4 25
99.0%
13.8%
Q3 25
99.4%
14.6%
Q2 25
99.5%
13.5%
Q1 25
99.6%
14.0%
Q4 24
12.6%
Q3 24
13.6%
Q2 24
13.6%
Q1 24
13.6%
Operating Margin
IBRX
IBRX
WYY
WYY
Q4 25
-169.0%
-1.9%
Q3 25
-173.5%
-1.3%
Q2 25
-269.8%
-1.9%
Q1 25
-390.1%
-2.4%
Q4 24
-919.0%
-0.8%
Q3 24
-1314.3%
-1.3%
Q2 24
-1.3%
Q1 24
-1.9%
Net Margin
IBRX
IBRX
WYY
WYY
Q4 25
-161.8%
-2.0%
Q3 25
-209.8%
-1.5%
Q2 25
-350.3%
-1.6%
Q1 25
-784.9%
-2.1%
Q4 24
-783.4%
-0.9%
Q3 24
-1404.0%
-1.2%
Q2 24
-1.4%
Q1 24
-1.9%
EPS (diluted)
IBRX
IBRX
WYY
WYY
Q4 25
$-0.06
$-0.08
Q3 25
$-0.07
$-0.06
Q2 25
$-0.10
$-0.06
Q1 25
$-0.15
$-0.08
Q4 24
$-0.08
$-0.05
Q3 24
$-0.14
$-0.04
Q2 24
$-0.05
Q1 24
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
WYY
WYY
Cash + ST InvestmentsLiquidity on hand
$242.8M
$9.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$-500.5M
$11.5M
Total Assets
$501.9M
$79.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
WYY
WYY
Q4 25
$242.8M
$9.8M
Q3 25
$257.8M
$12.1M
Q2 25
$153.7M
$6.8M
Q1 25
$61.6M
$3.7M
Q4 24
$149.8M
$6.8M
Q3 24
$130.4M
Q2 24
Q1 24
Stockholders' Equity
IBRX
IBRX
WYY
WYY
Q4 25
$-500.5M
$11.5M
Q3 25
$-524.3M
$12.2M
Q2 25
$-570.7M
$12.6M
Q1 25
$-591.4M
$13.0M
Q4 24
$-489.1M
$13.6M
Q3 24
$-745.1M
$13.8M
Q2 24
$14.0M
Q1 24
$14.2M
Total Assets
IBRX
IBRX
WYY
WYY
Q4 25
$501.9M
$79.8M
Q3 25
$519.0M
$70.6M
Q2 25
$402.1M
$76.6M
Q1 25
$303.8M
$71.4M
Q4 24
$382.9M
$71.6M
Q3 24
$364.6M
$56.9M
Q2 24
$58.6M
Q1 24
$54.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
WYY
WYY
Operating Cash FlowLast quarter
$-70.4M
$-173.5K
Free Cash FlowOCF − Capex
$-71.3M
$-270.0K
FCF MarginFCF / Revenue
-186.2%
-0.6%
Capex IntensityCapex / Revenue
2.4%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-308.8M
$5.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
WYY
WYY
Q4 25
$-70.4M
$-173.5K
Q3 25
$-68.9M
$5.9M
Q2 25
$-79.7M
$3.2M
Q1 25
$-85.9M
$-3.2M
Q4 24
$-85.1M
$2.4M
Q3 24
$-98.8M
$1.9M
Q2 24
$-1.1M
Q1 24
$-1.6M
Free Cash Flow
IBRX
IBRX
WYY
WYY
Q4 25
$-71.3M
$-270.0K
Q3 25
$-69.6M
$5.9M
Q2 25
$-80.8M
$3.1M
Q1 25
$-87.0M
$-3.3M
Q4 24
$-87.3M
$2.4M
Q3 24
$-101.6M
$1.8M
Q2 24
$-1.1M
Q1 24
$-1.6M
FCF Margin
IBRX
IBRX
WYY
WYY
Q4 25
-186.2%
-0.6%
Q3 25
-217.2%
16.4%
Q2 25
-305.9%
8.1%
Q1 25
-526.9%
-9.5%
Q4 24
-1155.4%
6.4%
Q3 24
-1663.2%
5.3%
Q2 24
-3.0%
Q1 24
-4.6%
Capex Intensity
IBRX
IBRX
WYY
WYY
Q4 25
2.4%
0.2%
Q3 25
2.3%
0.1%
Q2 25
4.1%
0.2%
Q1 25
6.8%
0.1%
Q4 24
28.0%
0.1%
Q3 24
45.7%
0.2%
Q2 24
0.0%
Q1 24
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IBRX
IBRX

Segment breakdown not available.

WYY
WYY

Carrier Services$26.8M63%
Managed Services$15.5M37%

Related Comparisons